Lexeo Expands Friedreich Ataxia Pipeline Through Mantle Deal, New Collaborations

Lexeo Therapeutics, Inc. (LXEO) is strengthening its position in Friedreich ataxia through the planned acquisition of Mantle Therapeutics and the launch of patients living with the rare genetic disease.